Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO ) by John F. Heerdink, Jr. 5 hours ago Read more The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN ) by John F. Heerdink, Jr. 3 days ago Read more Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX ) by John F. Heerdink, Jr. 3 days ago Read more Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. 4 days ago Read more Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI ) by John F. Heerdink, Jr. September 30, 2026 Read more Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB ) by John F. Heerdink, Jr. September 30, 2026 Read more AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI ) by John F. Heerdink, Jr. September 29, 2026 Read more Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI ) by John F. Heerdink, Jr. September 28, 2026 Read more Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER ) by John F. Heerdink, Jr. September 25, 2026 Read more Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24 by John F. Heerdink, Jr. September 23, 2026 Read more Read more
Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )